2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Ocular Motor Findings in Spinocerebellar Ataxia Type 17

SU. Lee, JY. Choi, JM. Kim, JS. Kim (Seoul, Republic of Korea)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Oligomeric Alpha-synuclein in Erythrocyte Membrane in Early Parkinson’s Disease

GL. Liu, C. Tian, T. Feng (Beijing, China)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Onset symptoms and time to diagnosis in Friedreich´s Ataxia

E. Indelicato, W. Nachbauer, A. Eigentler, M. Amprosi, P. Giunti, C. Mariotti, J. Arpa, A. Dürr, T. Klopstock, L. Schöls, T. Klockgether, K. Bürk, M. Pandolfo, J. Schulz, S. Boesch (Innsbruck, Austria)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Open-label safety and tolerability of L-Dihydroxyphenylserine (L-DOPS) and high dose carbidopa therapy in Parkinson’s disease patients

K. Hay, K. Mcdonell, P. Trujillo, M. Donahue, N. van Wouwe, D. Claassen (Nashville, TN, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression

J. Norton, D. Fredericks, G. Alva, J. Aldred, B. Coate, D. Dekarske, M. Cantillon, R. Owen (San Deigo, CA, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations

C. Liguori, M. Pierantozzi, R. Cerroni, NB. Mercuri, A. Stefani (Rome, Italy)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Opicapone and levodopa-carbidopa intestinal gel infusion: a cost saving analysis in the United Kingdom

V. Leta, D. van Wamelen, A. Sauerbier, S. Jones, A. Podlewska, D. Trivedi, M. Parry, P. Odin, A. Storch, Z. Pirtošek, A. Antonini, K. Ray Chaudhuri (London, United Kingdom)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials

R. Hauser, O. Rascol, W. Poewe, J. Ferreira, A. Lees, O. Klepitskaya, G. Liang, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Tampa, FL, USA)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3